Service to manufacturing companies has long been one of the bedrock foundations of our law firm. Today, with decades of experience under our belt, we understand the numerous legal, regulatory, operational, and financial issues that manufacturing companies face. As the industry undergoes a monumental transformation, we are uniquely positioned to assist clients in addressing significant shifts in their operations and serve as their “industry” law firm.
We are well-versed in key trends confronting our clients in the industry. There are the advanced technologies such as artificial intelligence, robotics, and blockchain having a dramatic effect on manufacturers’ R&D, supply chain management, production, and sales. One overarching trend, the Internet of Things, allows manufacturers to manage the maintenance of machines in a predictive and prescriptive way. Integrated and networked sensors and intelligent devices can predict and detect issues and prescribe improvements in one device or an entire plant.
Manufacturer and supplier integration is another evolving issue we help manufacturers address. We work with them to think through the desired objectives, long-term effect, and inherent risks of integration. We also navigate them through the complex web of global supply chain risks to realize the rewards of proactive engagement in modern ethical supply chain practice.
Yet another movement in the industry is renewable energy. Manufacturers are pivoting away from fossil fuels, and versatility of methods like biomass, solar thermal systems, and electrification make them top replacement options.
From day-to-day business issues to innovative advances in your operations, our lawyers can provide a wide range of services to meet your needs.
On 23 December 2020, Judge Catherine Blake of the U.S. District Court for the District of Maryland granted the Pharmaceutical Research and Manufacturers of America (PhRMA) a 14-day nationwide temporary restraining order, preventing the Centers for Medicare and Medicaid Services (CMS) from implementing and enforcing its Most Favored Nation (MFN) interim final rule (MFN Rule) scheduled to take effect on 1 January 2021.
Following earlier announcements as to the efficacy of vaccine trials by pharmaceutical companies Pfizer, Inc. (Pfizer) and Moderna, Inc. on November 20, 2020, Pfizer and BioNTech submitted applications for emergency use authorization to the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccinations.
This alert provides a brief overview of the final rules and the potential policy tools available to the Biden administration should it seek to revisit them.
We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.
